Isolation Or Purification Patents (Class 530/305)
  • Publication number: 20150045533
    Abstract: The present invention relates to a sorbent comprising a solid support material, the surface of which comprises a residue of a general formula (I), wherein the residue is attached via a covalent single bond to a functional group on the surface of either the bulk solid support material itself or of a polymer film on the surface of the solid support material.
    Type: Application
    Filed: September 17, 2012
    Publication date: February 12, 2015
    Inventors: Markus Arendt, Björn Degel, Thomas Schwarz, Gerhard Stumm, Martin Welter
  • Publication number: 20140336355
    Abstract: The present invention relates to a crosslinked sulphonated polymer or a crosslinked sulphonated polymer coated with a crosslinked polymer containing amino groups for use as an ion exchanger material of high salt tolerance for separating off macromolecules from a solution which originates from a biological source.
    Type: Application
    Filed: July 12, 2012
    Publication date: November 13, 2014
    Applicant: INSTRACTION GMBH
    Inventors: Markus Arendt, Gerhard Stumm, Martin Welter, Thomas Schwarz
  • Publication number: 20140323687
    Abstract: The present invention relates to a method for the isolation of proteins that comprise disulfide-bonds in their native conformation. Essentially, a method of the present makes the use of reducing agents such as ?-mercaptoethanol or dithiothreitol in protein isolation methods obsolete. A method of the present invention is particularly suitable for the isolation of precursor proteins such as proinsulin from recombinant cells.
    Type: Application
    Filed: July 8, 2014
    Publication date: October 30, 2014
    Inventors: Peter Van Der Meijden, Gijsbert Willem Karel Van Dedem, Michel Hendrikus Maria Eppink, Roeland Wilhelmus Wassenaar
  • Publication number: 20140243498
    Abstract: The present invention is within the field of biomolecule purification. More closely the invention relates to chromatographic purification of insulin using a specific kind of shell beads having an inner core and an outer functionalized layer. The method enables purification at high flow rates and high purity, over 90%.
    Type: Application
    Filed: September 28, 2012
    Publication date: August 28, 2014
    Inventors: Eggert Brekkan, Kjell Eriksson, Bo-Lennart Johansson, Jamil Shanagar
  • Publication number: 20140228539
    Abstract: The invention relates to a process for separating acetylated proteins from unacetylated proteins. In particular, the invention relates to a process of using multimodal chromatography to separate acetylated proteins from unacetylated proteins. In the prior art, multimodal chromatography is used to isolate antibodies. The invention found that multimodal chromatography can be used in the separation of acetylated proteins from unacetylated proteins.
    Type: Application
    Filed: April 18, 2014
    Publication date: August 14, 2014
    Applicants: TANVEX BIOLOGICS CORP., LA JOLLA BIOLOGICS, INC.
    Inventors: Kuo-Ming YU, Judy Huei-chuan CHOU, Jennifer Renee HOPP
  • Patent number: 8802816
    Abstract: The invention relates to methods of separation and/or purification of impurities yielding a purified heterologous protein product devoid of related impurities or with substantially minimal quantities of such glycosylated impurities. More specifically, the invention relates to the identification of glycosylated forms of insulin analogues such as glargine impurities characterized post expression in yeast based systems such as Pichia pastoris. The invention also relates to methods used to clone gene encoding the protein insulin glargine; inserting the related gene in a suitable yeast host; producing culture of the recombinant strain, stimulating expression of the heterologous polypeptide, its secretion and purification post fermentation and related enzymatic conversions.
    Type: Grant
    Filed: April 3, 2008
    Date of Patent: August 12, 2014
    Assignee: Biocon Limited
    Inventors: Partha Hazra, Nitesh Dave, Vivekanandan Kannan, Sanjay Tiwari, Anuj Goel, Harish Iyer, Nita Roy, Krishnamurthy Venkatesan, Anoop Vasudevan, Anupama Jagadish, Goldy Sachdev, Mukesh Babuappa Patale
  • Publication number: 20140155574
    Abstract: Disclosed is a method for preparing an insulin glargine (GlyA21-ArgB31-AryB32-human insulin) crystal, comprising crystallizing the insulin glargine at pH 7.0-9.0 and in a crystallization solution containing a recombinant insulin glargine, an organic solvent of a 10-30% concentration by volume, a zinc compound, a phenol derivative, a salt and an organic acid.
    Type: Application
    Filed: April 19, 2012
    Publication date: June 5, 2014
    Applicant: GAN & LEE PHARMACEUTICALS
    Inventors: Damei Wang, Wenjie Li, Jinlei Zhang
  • Publication number: 20140073759
    Abstract: The present application discloses a chromatographic process for separating protein components of a protein-containing solution, said solution comprising an insulin peptide and one or more di- or polyvalent metal ions, said insulin peptide being capable of self-association and/or structural change in the presence of di- or polyvalent metal ions, said process comprising the steps of: a) applying the protein-containing solution to a column of a chromatographic solid phase material, wherein the loading of the insulin peptide is at least 6.0 g per litre of column volume (g/Lcv); and b) eluting the insulin peptide from said solid phase material by means of an eluent having a pH of at the most 8.5; and collecting a pool of the insulin peptide corresponding to at least 75% by weight of the insulin peptide applied to the column in step (a).
    Type: Application
    Filed: February 1, 2012
    Publication date: March 13, 2014
    Applicant: Novo Nordisk A/S
    Inventors: Joergen M. Mollerup, Soeren Soendergaarad Frederiksen
  • Patent number: 8669418
    Abstract: The present invention belongs to the field of functional proteomics and more particularly to the field of protein aggregation. The invention discloses a method for interfering with the function of a target protein and uses a non-naturally, user-designed molecule, designated as interferor, that has a specificity for a target protein and which induces aggregation upon contact with said target protein. The present invention also discloses such interferor molecules and their use in agrobiotech applications.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: March 11, 2014
    Assignees: VIB VZW, Vrije Universiteit Brussel
    Inventors: Joost Schymkowitz, Frederic Rousseau
  • Publication number: 20130338064
    Abstract: Provided are an insulin-lipid complex, a preparation method thereof, and a formulation thereof. The insulin-lipid complex is prepared by compounding insulin and a lipid material in an organic solvent system containing a low boiling point acid, and drying. The mass ratio of insulin to the lipid material is 1:3˜1:20. An oil solution of the insulin-lipid complex and vesicles containing insulin are further provided.
    Type: Application
    Filed: July 14, 2011
    Publication date: December 19, 2013
    Applicant: Institute of Materia Medica, Chinese Academy of Medical Sciences
    Inventors: Yuling Liu, Cuiping Zhou, Zhihui Song, Lin Li, Hongliang Wang, Xuejun Xia, Renyun Wang, Wujun Dong, Dujia Jin
  • Publication number: 20130323812
    Abstract: Methods and compositions are provided for treatment of an apatite-based resin from which retained solutes have been eluted by an elution buffer that contains an alkali metal salt with solutions of calcium ion, phosphate ion, and hydroxide separately from any sample loading and elution buffers. The treatment solutions restore the resin, reversing the deterioration that is caused by the alkali metal salt in the elution buffer.
    Type: Application
    Filed: May 10, 2013
    Publication date: December 5, 2013
    Applicant: Bio-Rad Laboratories, Inc.
    Inventors: Larry J. Cummings, Jie He
  • Patent number: 8569227
    Abstract: A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof, exhibit enhanced thermal and chemical stability while presenting six modifiable loop domains which can be engineered to form a binding partner capable of binding to a target for applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: October 29, 2013
    Assignee: Janssen Biotech, Inc.
    Inventor: Steven Jacobs
  • Publication number: 20130150553
    Abstract: The present invention relates to a method for the isolation of proteins that comprise disulfide bonds in their native conformation. Essentially, a method of the present invention makes use of reducing agents such as ?-mercaptoethanol or dithiothreitol in protein isolation methods obsolete. A method of the present invention is particularly suitable for the isolation of precursor proteins such as proinsulin from recombinant cells.
    Type: Application
    Filed: May 9, 2012
    Publication date: June 13, 2013
    Inventors: Peter Van Der Meijden, Gijsbert Willem Karel Van Dedem, Michel Hendrikus Maria Eppink, Roeland Wilhelmus Wassenaar
  • Publication number: 20130012684
    Abstract: The present invention provides a method for purification of a protein that is conjugated to an albumin binding moiety from a mixture comprising (i) said protein in said conjugated form and (ii) said protein in a form that is not conjugated to said albumin-binding moiety, the method comprising: (a) providing a solid support comprising a substance capable of specifically binding to the albumin binding moiety; (b) contacting said solid support of (a) with said mixture comprising protein and conjugated protein under suitable conditions for binding of the albumin binding moiety to the substance as defined in (a); and (c) eluting components bound to the solid support.
    Type: Application
    Filed: February 3, 2011
    Publication date: January 10, 2013
    Applicant: Novo Nordisk A/S
    Inventor: Jens Buchardt
  • Publication number: 20120214966
    Abstract: A process is disclosed for separating biomolecules from an aqueous solution containing the biomolecules and impurities, having different affinities and/or interactions with a solid support. The solution is passed over a fixed bed of chromatographic resin containing at least three zones, with flow of liquid being arranged between adjacent zones and between a last and first zone. Each of several sequences includes at least an adsorption stage, a rinsing stage, or a desorption stage, with each subsequent sequence being carried out by a downstream displacement of fronts in the zones by approximately the same increment before the periodical displacement of the introduction and withdrawal points.
    Type: Application
    Filed: April 17, 2012
    Publication date: August 23, 2012
    Applicant: GROUPE NOVASEP
    Inventors: Marc-André Theoleyre, Stanislas Baudouin, Annick Merrien, Eric Valery, Olivier Ludemann-Hombourger, David Laurent, Margit Holzer
  • Publication number: 20120178900
    Abstract: The present disclosure demonstrates the utility of ion pairing agents in the preparative scale of purification. More particularly, the disclosure relates to the usage of ion pairing agents in RP preparative linear chromatography enabling high purity of the desired end product. The disclosure shows that ion-pairing agents have dramatic effect on desired purity of polypeptides.
    Type: Application
    Filed: August 9, 2010
    Publication date: July 12, 2012
    Applicant: BIOCON LIMITED
    Inventors: Nitesh Dave, Krishana Chaitanya Gulla, Sundaresh Shankar, Harish Iyer
  • Publication number: 20120123089
    Abstract: The instant disclosure provides a method for purification of peptides by chromatographic techniques. The proposed methodology will help in addressing the problems associated in purifying biological protein products emerging from the evolving biotechnology industry.
    Type: Application
    Filed: July 8, 2010
    Publication date: May 17, 2012
    Applicant: BIOCON LIMITED
    Inventors: Nitesh Dave, Devesh Radhakrishnan, Sundaresh Shankar, Krishanachaitanya Gulla, Harish Iyer
  • Patent number: 8058391
    Abstract: The invention claims a process for making an insulin-oligomer conjugate IN-105. IN-105 precursor having formula G-A-V-R-[B-Chain]-R-D-A-D-D-R-[A-Chain] is cloned and expressed in Pichia. The biosynthetic precursor is then conjugated with an activated oligomer. The IN-105 precursor-oligomer conjugate is then treated with protease and purified to afford active insulin-oligomer conjugate of formula insulin-OC—CH2—CH2—(OCH2CH2)3—OCH3.
    Type: Grant
    Filed: October 13, 2005
    Date of Patent: November 15, 2011
    Assignee: Biocon Limited
    Inventors: Nitesh Dave, Partha Hazra, Anuj Goel, Nita Roy, Anand Khedkar, Harish Iyer, Gautam Krishnan, H. S. Manjunath, Shrikumar Suryanarayan, Govindasamy Manikam, Goldy Sachdev, Mayank Garg
  • Patent number: 7884181
    Abstract: The invention provides a pharmaceutical formulation and a method for preparing the formulation.
    Type: Grant
    Filed: October 5, 2005
    Date of Patent: February 8, 2011
    Assignee: Novo Nordisk A/S
    Inventors: Petter Lybeck (Berglund), Charlotte Hammelev, Lone Eskildsen, Johanne Madsen, Helle Aalund Olsen, Lone Kimer
  • Publication number: 20100233783
    Abstract: Process for purifying a recombinant protein including one or a few procedural steps only. The process combines the step of lysis of the host cell, with the purification of the protein of interest, allowing for a rapid and much more efficient process of purification. The conditions used during the purification process are those of a high temperature and a low pH, allowing for thermostable and acid-resistant recombinant proteins to be isolated from a suspension. The invention also relates to purifying recombinant proteins which are fusion proteins, wherein one part of the protein may be selected from an enamel matrix protein, such as amelogenin.
    Type: Application
    Filed: March 23, 2006
    Publication date: September 16, 2010
    Applicant: Straumann Holding AG
    Inventors: Johan Per Henrik Svensson, Leif Bülow
  • Patent number: 7763706
    Abstract: Described is a method for the preparation of a mixture of peptides, having an arginine and lysine content of at least 20 w/w %, based on the protein content, from at least one protein source, to a preparation comprising a mixture of arginine- and lysine-rich peptides, comprising at least 20 w/w % arginine and lysine, and to the use of the said preparation as active compound in a medicament, supplement, beverage or food product.
    Type: Grant
    Filed: July 11, 2003
    Date of Patent: July 27, 2010
    Assignee: Campina B.V.
    Inventors: Anita Dekker, Johanna Maria Henrica van der Steen
  • Publication number: 20100167374
    Abstract: The present invention relates to a chromatographic method of separating biological material comprising, providing chromatographic media comprising inorganic oxide particles having an average diameter of about 2 microns or less and an average pore diameter of 300 ? or more; applying a solvent comprising said biological material to said media, wherein said biological material is reversibly bonded to said media; and eluting said biological material from said media with a solvent in less than about 2 minutes for biological material having a molecular weight of less than about 100,000 Daltons.
    Type: Application
    Filed: February 21, 2008
    Publication date: July 1, 2010
    Inventors: Reno T. Nguyen, Scott Anderson, Ian Chappell
  • Patent number: 7550558
    Abstract: This invention relates to a method for identifying peptides having antimicrobial activity and to the antimicrobial peptides identified thereby and methods for their use.
    Type: Grant
    Filed: June 1, 2001
    Date of Patent: June 23, 2009
    Assignee: Fundacao de Ampara a Pesquiso do Estado de Sao Paolo (FAPESP)
    Inventors: Adilson Leite, Urara Kawazoe, Paulo Arruda, Arnaldo da Silva Junior
  • Patent number: 7534857
    Abstract: A biologically pure RNAIII inhibiting peptide (RIP), that includes five contiguous amino acids of the sequence YX2PX1TNF, where X1 is C, W, I or a modified amino acid, and X2 is K or S is provided. The RIP further includes amino acids having a sequence that differs from the sequence YX2PX1TNF by two substitutions or deletions, where X1 is C, W, I or a modified amino acid, and X2 is K or S. This agent offers improved protection against and treatment of staphylococcal infections, and related bacteria infections, in mammals.
    Type: Grant
    Filed: May 1, 2006
    Date of Patent: May 19, 2009
    Assignee: Centegen, Inc.
    Inventor: Naomi Balaban
  • Patent number: 7507787
    Abstract: A method of identifying a polynucleotide or pattern of polynucleotides regulated by one or more sepsis or inflammatory inducing agents and inhibited by a peptide is described. A method of identifying a pattern of polynucleotide expression for inhibition of an inflammatory or septic response. The method includes contacting cells with LPS, LTA, CpG DNA and/or intact microbe or microbial components in the presence or absence of a cationic peptide; detecting a pattern of polynucleotide expression for the cells in the presence and absence of the peptide, wherein the pattern in the presence of the peptide represents inhibition of an inflammatory or septic response. Also included are compounds and agents identified by the methods of the invention. In another aspect, the invention provides methods and compounds for enhancing innate immunity in a subject.
    Type: Grant
    Filed: December 2, 2002
    Date of Patent: March 24, 2009
    Assignee: The University of British Columbia
    Inventors: Robert E. W. Hancock, B. Brett Finlay, Monisha Gough Scott, Dawn Bowdish, Carrie Melissa Rosenberger, Jon-Paul Steven Powers
  • Patent number: 7431936
    Abstract: The present invention provides the RSP-1 and RSP-2 proteins which are involved in the cytoadhesion of P. falciparum during ring-stage infection of erythrocytes, antibodies which bind to the proteins, methods of screening for a P. falciparum infection, methods of determining the infective stage of P. falciparum and vaccines for protecting individuals from Plasmodium sp. infections.
    Type: Grant
    Filed: November 29, 2002
    Date of Patent: October 7, 2008
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Juerg Gysin, Bruno Pouvelle, Artur Scherf, Pierre Buffet
  • Patent number: 7402653
    Abstract: Thirty substantially pure and biologically active peptides are disclosed. Nucleic acids that have sequences coding for the biologically active peptides and pharmaceutical formulations produced thereform are also disclosed.
    Type: Grant
    Filed: June 16, 2006
    Date of Patent: July 22, 2008
    Assignee: CMS Peptides Patent Holding Company Limited
    Inventors: Wai Ming Wong, Kong Lam
  • Publication number: 20080139784
    Abstract: The present invention discloses a process for making an insulin-oligomer conjugate as a one-pot reaction by conjugation of insulin-ester with an activated oligomer wherein simultaneous deblocking and conjugation is carried out.
    Type: Application
    Filed: July 8, 2005
    Publication date: June 12, 2008
    Applicant: Biocon Limited
    Inventors: Partha Hazra, H.S. Manjunath, Anand Khedkar, Harish Iyer, Nitesh Dave, Gautam Krishnan, Shrikumar Suryanarayan
  • Patent number: 7378390
    Abstract: Novel insulin precursors and insulin precursor analogs comprising a connecting peptide (mini C-peptide) of preferably up to 15 amino acid residues and comprising at least one Gly are provided. The precursors can be converted into human insulin or a human insulin analog. The precursors will typically have a distance between B27 (atom CG2) and A1 (atom CA) of less than 5 ?.
    Type: Grant
    Filed: July 19, 2004
    Date of Patent: May 27, 2008
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Børglum Kjeldsen, Svend Ludvigsen
  • Publication number: 20080108787
    Abstract: This invention describes processes for purification of insulin or insulin-like material by reverse phase chromatography by using polystyrenic resins as the chromatographic materials. in particular the present invention describes processes for the purification of a particular insulin-like material from chemically and structurally similar contaminants.
    Type: Application
    Filed: May 24, 2004
    Publication date: May 8, 2008
    Inventors: Maharaj K Sahib, Edupuganti B Raju, Sivaraman Subramaniam, Vennapusa R Reddy
  • Patent number: 7202044
    Abstract: The invention relates to defined peptides and the quantitative determination thereof in body fluids of patients suffering from progredient chronic dementia, in relation to the concentration of said peptides in a control group. The inventive peptides come from a protein precursor having the corresponding gene, are processed in a specific manner, and are optionally post-translationally modified, especially phosphorylized. An increase in the concentrations of these peptides or the corresponding non-processed protein indicates progredient chronic dementia. Progredient chronic dementia is detected by identifying the peptides and/or the protein individually or in combinations. The invention also relates to the use of said peptides for controlling the course of progredient chronic dementia and for the prognosis of progredient chronic dementia, especially for complementing or replacing mini-mental scores, and for developing therapeutic agents to combat progredient chronic dementia such as Alzheimer's disease.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: April 10, 2007
    Assignee: Biovision AG
    Inventors: Norbert Lamping, Hans-Dieter Zucht, Harmut Selle, Michael Jürgens, Gabriele Heine, Rüdiger Hess
  • Patent number: 7193034
    Abstract: The invention provides methods and compositions useful for making synthetic peptide conjugates. In one embodiment, the invention provides compositions comprising the structure: wherein R is selected from lower substituted or unsubstituted alkyl, O, NH and S and P is an amine protection group. In more particular embodiments, the compositions comprise ?-amine protected 4,5-dehydroleucine or ?-amine protected (2S)-aminolevulinic acid and/or P is F-moc. These compounds may be incorporated into peptides, for example, peptides comprising a substituted or unsubstituted (2S)-aminolevulinic acid residue, such as (2S)-aminolevulinic acid residue is substituted with an O- or N-linked glycoconjugate, or a detectable label.
    Type: Grant
    Filed: September 6, 2005
    Date of Patent: March 20, 2007
    Assignee: Regents of the University of California
    Inventor: Carolyn R. Bertozzi
  • Patent number: 7094580
    Abstract: A method of perlecan isolation (from the EHS tumor) which produces “clean” (i.e. substantially “pure”) perlecan is disclosed. Clean perlecan is thus produced in sufficient quantities for use in a number of different in vitro and in vivo assays. In addition, this isolation method exploits a newly discovered aggregating property of a ˜220 kDa heparan sulfate proteoglycan (HSPG) observed during gel filtration chromatography, which allows it to be effectively separated from non-aggregating perlecan. The method employs specific cation exchange, anion exchange, molecular sieve chromatography and immobilized GAG affinity chromatography. It is demonstrated that there are no other contaminating proteins in the perlecan and HSPG preparations, and that the perlecan core protein is intact. Improved, clean perlecan based, rodent models of fibrillar amyloid protein deposition, accumulation and/or persistence in tissues are disclosed.
    Type: Grant
    Filed: December 18, 2002
    Date of Patent: August 22, 2006
    Assignee: University of Washington
    Inventors: Gerardo Castillo, Alan D. Snow
  • Patent number: 7087408
    Abstract: Novel insulin precursors and insulin precursor analogs having a mini C-peptide comprising at least one aromatic amino acid residue have an increased folding stability. The novel insulin precursors and insulin precursor analogs can be expressed in yeast in high yields and are preferably not more 15 amino acid residues in length. Also provided are polynucleotide sequences encoding the claimed precursors or precursor analogs, and vectors and cell lines containing such polynucleotide sequences.
    Type: Grant
    Filed: December 11, 2002
    Date of Patent: August 8, 2006
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Borglum Kjeldsen, Svend Ludvigsen, Niels C. Kaarsholm
  • Patent number: 7074415
    Abstract: Streptococcus polypeptides and polynucleotides encoding them are disclosed. The polypeptides may be useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.
    Type: Grant
    Filed: June 20, 2001
    Date of Patent: July 11, 2006
    Assignee: ID Biomedical Corporation
    Inventors: Josée Hamel, Catherine Ouellet, Nathalie Charland, Denis Martin, Bernard Brodeur
  • Patent number: 7041783
    Abstract: In accordance with the present invention, there are provided novel Survivin-binding-proteins (SBPs). Nucleic acid sequences encoding such proteins and assays employing same are also disclosed. The invention SBPs can be employed in a variety of ways, for example, for the production of anti-SBP antibodies thereto, in therapeutic compositions and in bioassays methods employing such proteins and/or antibodies. Also provided are transgenic non-human mammals that express the invention protein.
    Type: Grant
    Filed: January 24, 2002
    Date of Patent: May 9, 2006
    Assignee: The Burnham Institute
    Inventors: John C. Reed, Kazuya Okada
  • Patent number: 7037654
    Abstract: Probe sets for the multiplexed detection of the binding of, or interaction between, one or more ligands and target antiligands are provided. Detection involves the release of identifying tags as a consequence of target recognition. The probe sets include electrophoretic tag probes or e-tag probes, comprising a detection region and a mobility-defining region called the mobility modifier, both linked to a target-binding moiety. The probes comprise interactive functionalities adjacent the cleaved portion positioned in the probes such that the interactive functionality does not form part of the e-tag reporters. Target antiligands are contacted with a set of e-tag probes and the contacted antiligands are treated with a selected cleaving agent resulting in a mixture of e-tag reporters and uncleaved and/or partially cleaved e-tag probes. The mixture is exposed to a capture agent effective to bind to uncleaved or partially cleaved e-tag probes, followed by electrophoretic separation.
    Type: Grant
    Filed: November 9, 2001
    Date of Patent: May 2, 2006
    Assignee: Aclara Biosciences, Inc.
    Inventors: Ahmed Chenna, Sharat Singh
  • Patent number: 6939945
    Abstract: The invention provides methods and compositions useful for making synthetic peptide conjugates. In one embodiment, the invention provides compositions comprising the structure: wherein R is selected from lower substituted or unsubstituted alkyl, O, NH and S and P is an amine protection group. In more particular embodiments, the compositions comprise ?-amine protected 4,5-dehydroleucine or ?-amine protected (2S)-aminolevulinic acid and/or P is F-moc. These compounds may be incorporated into peptides, for example, peptides comprising a substituted or unsubstituted (2S)-aminolevulinic acid residue, such as (2S)-aminolevulinic acid residue is substituted with an O- or N-linked glycoconjugate, or a detectable label.
    Type: Grant
    Filed: October 10, 2002
    Date of Patent: September 6, 2005
    Assignee: The Regents of the University of California
    Inventors: Carolyn R. Bertozzi, Lisa A. Marcaurelle, Elena C. Rodriguez
  • Patent number: 6906028
    Abstract: The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment regimes requiring lengthy chemical and physical stability, such as, in continuous infusion systems.
    Type: Grant
    Filed: October 3, 2002
    Date of Patent: June 14, 2005
    Assignee: Eli Lilly and Company
    Inventors: Michael Rosario DeFelippis, Michael Allen Dobbins, Bruce Hill Frank, Shun Li, Dawn Marie Rebhun
  • Patent number: 6894023
    Abstract: A process for producing cation crystals of growth hormone or growth hormone derivatives, as well as growth hormone and growth hormone derivatives. The process of producing the growth hormone crystals includes the steps of (a) adding cations of inorganic or organic nature and an organic solvent or a mixture of inorganic solvents at a pH between 5.0 and 6.8 to a solution of growth hormone or derivatives. (b) growing growth hormone crystals at a temperature from about 0 to 30° C. and (c) isolating the cation crystals.
    Type: Grant
    Filed: June 12, 2000
    Date of Patent: May 17, 2005
    Assignee: Novo Nordisk A/S
    Inventors: Flemming Junker, Claus Friis Theisen
  • Patent number: 6875589
    Abstract: A mini-proinsulin, in which the amino acid Arg bridges the A and the B chain instead of the C chain, shows insulin activity and is suitable for the preparation of pharmaceuticals for the treatment of diabetes mellitus. It can furthermore be converted into an insulin derivative simply using trypsin, the B chain of which is lengthened by Arg. This can be converted into insulin using carboxypeptidase B. Advantageously, however, the mini-proinsulin can also be converted to insulin directly in a one-pot process.
    Type: Grant
    Filed: March 10, 1995
    Date of Patent: April 5, 2005
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Michael Dörschug, Paul Habermann, Gerhard Seipke, Eugen Uhlmann
  • Patent number: 6800606
    Abstract: Monomeric analogues of human insulin have a single substitution of the amino acid in 12th, 16th or the 26th position of the B chain of human insulin and may also have a terminal deletion in the B chain.
    Type: Grant
    Filed: March 8, 2002
    Date of Patent: October 5, 2004
    Assignee: Shanghai Institute of Biochemistry
    Inventors: Feng You-Min, You-Shang Zhang
  • Patent number: 6727346
    Abstract: The present invention relates to an improved process for obtaining a precursor of an insulin or insulin derivative having correctly bonded cystine bridges in the presence of cysteine or cysteine hydrochloride and chaotropic auxiliary.
    Type: Grant
    Filed: September 7, 2001
    Date of Patent: April 27, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Franz-Josef Rubröder, Reinhold Keller
  • Publication number: 20040077528
    Abstract: Methods are provided for purifying peptides and proteins by incorporating the peptide or protein into a diketopiperazine or competitive complexing agent to facilitate removal one or more impurities, i.e. undesirable components, from the peptide or protein. In a preferred embodiment, a peptide, such as insulin, containing one or more impurities, e.g., zinc ions, is entrapped in diketopiperazine to form a precipitate of peptide/diketopiperazine/impurity, which is then washed with a solvent for the impurity to be removed, which is a nonsolvent for the diketopiperazine and a nonsolvent for the peptide. Formulations and methods also are provided for the improved transport of active agents across biological membranes, resulting for example in a rapid increase in blood agent concentration.
    Type: Application
    Filed: November 21, 2003
    Publication date: April 22, 2004
    Applicant: MannKind Corporation
    Inventors: Solomon S. Steiner, Rodney J. Woods, Joseph W. Sulner
  • Patent number: 6723321
    Abstract: Provided are compositions and methods useful for modulating the activity of autoinducer synthase catalysts. A method for identifing modulators of the autoinducer synthesis reaction is also provided. Such modulators are useful for controlling bacterial growth and can be used for therapeutic treatment of bacterial infections particularly in immunocompromised subjects. They are also useful in treating disease states associated with autoinducer synthesis and biofilm development.
    Type: Grant
    Filed: January 6, 1999
    Date of Patent: April 20, 2004
    Assignees: The Board of Trustees of the University of Illinois, The University of Iowa Research Foundation
    Inventors: E. Peter Greenberg, John E. Cronan, Jr., Bryce V. Plapp, Matthew R. Parsek
  • Patent number: 6710167
    Abstract: The present invention relates to an improved procedure for the chromatographic purification of insulins wherein a pressure-stable organic polymeric chromatography material is used as a stationary phase, and the mobile phase contains at least one water-miscible organic solvent and at least one buffer substance and the pH is from about 7 to about 11.
    Type: Grant
    Filed: August 24, 1999
    Date of Patent: March 23, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Werner Sievers, Richard Bicker, Dieter Desch, Jörg Von Eysmondt, Reinhold Keller, Frank Richard
  • Publication number: 20030216543
    Abstract: Simulated moving beds for the chromatographic purification of insulin are provided. The insulin can be resolved from one or more components, using one or more simulated moving bed rings. Methods for designing simulated moving beds for the purification of insulin, and optimizing the operating parameters of the simulated moving beds, are also provided based upon the standing wave design.
    Type: Application
    Filed: April 7, 2003
    Publication date: November 20, 2003
    Inventors: Nien-Hwa Linda Wang, Yi Xie, Sungyong Mun
  • Publication number: 20030191277
    Abstract: Novel insulin precursors and insulin precursor analogs having a mini C-peptide comprising at least one aromatic amino acid residue have an increased folding stability. The novel insulin precursors and insulin precursor analogs can be expressed in yeast in high yields and are preferably not more 15 amino acid residues in length. Also provided are polynucleotide sequences encoding the claimed precursors or precursor analogs, and vectors and cell lines containing such polynucleotide sequences.
    Type: Application
    Filed: December 11, 2002
    Publication date: October 9, 2003
    Inventors: Thomas Borglum Kjeldsen, Svend Ludvigsen, Niels C. Kaarsholm
  • Publication number: 20030166834
    Abstract: Isolated polynucleotides encoding monkey Melanin Concentrating Hormone (MCH) Type 1 receptors and chimeric polypeptides are provided. Vectors and cells for recombinant expression of such MCH1R polypeptides, and isolated MCH1R polypeptides are also provided. MCH1R polynucleotides and polypeptides may be used, for example, to identify compounds that specifically interact with MCH receptor. Such compounds find use within therapies for humans and animals afflicted with conditions associated with MCH receptor activation.
    Type: Application
    Filed: April 18, 2002
    Publication date: September 4, 2003
    Inventors: Michele Bennett Kinrade, Robbin Brodbeck, James Krause
  • Publication number: 20030096947
    Abstract: A novel organic anion transporter gene participating in organic anion transport in the placenta; and an organic anion transporter which is a polypeptide encoded by the gene. A placental organic anion transporter OAT4, more particularly, a placental organic anion transporter OAT4 having the amino acid sequence represented by SEQ ID NO:2 or an amino acid sequence derived therefrom by deletion, substitution or addition of a part of the amino acids thereof. A nucleic acid (preferably DNA) having a base sequence encoding the placental organic anion transporter OAT4 or a base sequence hybridizable therewith under stringent conditions.
    Type: Application
    Filed: January 9, 2003
    Publication date: May 22, 2003
    Applicant: Japan Science and Technology Corporation, Japan
    Inventors: Hitoshi Endou, Takashi Sekine, Seok Ho Cha